Back to News
Market Impact: 0.3
What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Nuvation Bio reported $45 million in third-quarter 2026 revenue, while U.S. sales of its lung cancer treatment IBTROZI rose 18% quarter over quarter. The company also said new patient starts declined across the broader ROS1 treatment market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment
NUVB0.30
More News
- Here are the 2 big things we're watching in the stock market in the week ahead
- China AI bust threatens Xi’s ’Wall Street East’ ambitions
- As tech swoon roils market, US inflation data on tap
- Berkshire Hathaway speeds up stock buybacks, though profit falls
- Cabaletta Bio reports phase 1/2 data for autoimmune therapy
- Nvidia CEO Jensen Huang faces bipartisan congressional scrutiny over reported China spy link